The clinical outcomes of advanced EGFR-mutant NSCLC patients receiving first-line EGFR-TKIs may be significantly impacted by the subtypes of EGFR mutations [3, 8, 11, 24]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.